{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:18:46Z","timestamp":1794136726045,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41591-025-04043-5","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T10:02:06Z","timestamp":1767348126000},"page":"258-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1\/2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-1751","authenticated-orcid":false,"given":"Benjamin L.","family":"Musher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-9391","authenticated-orcid":false,"given":"Spyridoula","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8814-8004","authenticated-orcid":false,"given":"Brandon G.","family":"Smaglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-7160","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Kuvalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yovana","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamika","family":"Ketkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-6676","authenticated-orcid":false,"given":"Tamadar Al","family":"Doheyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope G.","family":"Papayanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Lapteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambi J.","family":"Grilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7637-3717","authenticated-orcid":false,"given":"George","family":"Van Buren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal D.","family":"Lulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm K.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4470-1760","authenticated-orcid":false,"given":"Ann M.","family":"Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"4043_CR1","doi-asserted-by":"crossref","unstructured":"Dreyer, S. B., Beer, P., Hingorani, S. R. & Biankin, A. V. Improving outcomes of patients with pancreatic cancer. Nat. Rev. Clin. Oncol. 22, 439\u2013456 (2025).","DOI":"10.1038\/s41571-025-01019-9"},{"key":"4043_CR2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3, 272\u2013286 (2022).","journal-title":"Nat. Cancer"},{"key":"4043_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu, Z. I. & O\u2019Reilly, E. M. Therapeutic developments in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 7\u201324 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"4043_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155, 29\u201332 (2018).","journal-title":"Gastroenterology"},{"key":"4043_CR5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/cells13010101","volume":"13","author":"A Czaplicka","year":"2024","unstructured":"Czaplicka, A., Lachota, M., Paczek, L., Zagozdzon, R. & Kaleta, B. Chimeric antigen receptor T cell therapy for pancreatic cancer: a review of current evidence. Cells 13, 101 (2024).","journal-title":"Cells"},{"key":"4043_CR6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s12029-024-01054-2","volume":"55","author":"K Drougkas","year":"2024","unstructured":"Drougkas, K. et al. CAR-T Cell therapy in pancreatic and biliary Tract cancers: an updated review of clinical trials. J. Gastrointest. Cancer 55, 990\u20131003 (2024).","journal-title":"J. Gastrointest. Cancer"},{"key":"4043_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","volume":"24","author":"EF Giurini","year":"2025","unstructured":"Giurini, E. F., Ralph, O., Pappas, S. G. & Gupta, K. H. Looking beyond checkpoint inhibitor monotherapy: uncovering new frontiers for pancreatic cancer immunotherapy. Mol. Cancer Ther. 24, 18\u201332 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"4043_CR8","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"4043_CR9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919\u20131929 (2019).","journal-title":"Mol. Ther."},{"key":"4043_CR10","doi-asserted-by":"crossref","first-page":"1429330","DOI":"10.3389\/fonc.2024.1429330","volume":"14","author":"SR Paredes-Moscosso","year":"2024","unstructured":"Paredes-Moscosso, S. R. & Nathwani, A. C. 10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer. Front. Oncol. 14, 1429330 (2024).","journal-title":"Front. Oncol."},{"key":"4043_CR11","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J. Clin. Oncol. 42, 2565\u20132577 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4043_CR12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/EDBK_175232","volume":"37","author":"GL Beatty","year":"2017","unstructured":"Beatty, G. L., Eghbali, S. & Kim, R. Deploying immunotherapy in pancreatic cancer: defining mechanisms of response and resistance. Am. Soc. Clin. Oncol. Educ. Book 37, 267\u2013278 (2017).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"4043_CR13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","volume":"40","author":"K Li","year":"2022","unstructured":"Li, K. et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell 40, 1374\u20131391 (2022).","journal-title":"Cancer Cell"},{"key":"4043_CR14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"4043_CR15","volume":"16","author":"RPG Ramesh","year":"2025","unstructured":"Ramesh, R. P. G. et al. Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma. Front. Immunol. 16, 1573522 (2025).","journal-title":"Front. Immunol."},{"key":"4043_CR16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","volume":"26","author":"M Shakiba","year":"2025","unstructured":"Shakiba, M. & Tuveson, D. A. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nat. Immunol. 26, 678\u2013691 (2025).","journal-title":"Nat. Immunol."},{"key":"4043_CR17","doi-asserted-by":"crossref","first-page":"e145389","DOI":"10.1172\/jci.insight.145389","volume":"6","author":"MM Wattenberg","year":"2021","unstructured":"Wattenberg, M. M. et al. Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. JCI Insight 6, e145389 (2021).","journal-title":"JCI Insight"},{"key":"4043_CR18","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","volume":"19","author":"U Gerdemann","year":"2011","unstructured":"Gerdemann, U. et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol. Ther. 19, 2258\u20132268 (2011).","journal-title":"Mol. Ther."},{"key":"4043_CR19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221107113","volume":"14","author":"V Hoyos","year":"2022","unstructured":"Hoyos, V. et al. Multi-antigen-targeted T-cell therapy to treat patients with relapsed\/refractory breast cancer. Ther. Adv. Med Oncol. 14, 17588359221107113 (2022).","journal-title":"Ther. Adv. Med Oncol."},{"key":"4043_CR20","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","volume":"137","author":"PD Lulla","year":"2021","unstructured":"Lulla, P. D. et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant. Blood 137, 2585\u20132597 (2021).","journal-title":"Blood"},{"key":"4043_CR21","doi-asserted-by":"crossref","first-page":"eaaz3339","DOI":"10.1126\/scitranslmed.aaz3339","volume":"12","author":"PD Lulla","year":"2020","unstructured":"Lulla, P. D. et al. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci. Transl. Med. 12, eaaz3339 (2020).","journal-title":"Sci. Transl. Med."},{"key":"4043_CR22","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2021014648","volume":"139","author":"S Naik","year":"2022","unstructured":"Naik, S. et al. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood 139, 2706\u20132711 (2022).","journal-title":"Blood"},{"key":"4043_CR23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","volume":"39","author":"S Vasileiou","year":"2021","unstructured":"Vasileiou, S. et al. T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects. J. Clin. Oncol. 39, 1415\u20131425 (2021).","journal-title":"J. Clin. Oncol."},{"key":"4043_CR24","doi-asserted-by":"crossref","first-page":"e93321","DOI":"10.1371\/journal.pone.0093321","volume":"9","author":"D Abate-Daga","year":"2014","unstructured":"Abate-Daga, D. et al. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS ONE 9, e93321 (2014).","journal-title":"PLoS ONE"},{"key":"4043_CR25","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ads4227","volume":"11","author":"D Armstrong","year":"2025","unstructured":"Armstrong, D. et al. MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. Sci. Adv. 11, eads4227 (2025).","journal-title":"Sci. Adv."},{"key":"4043_CR26","doi-asserted-by":"crossref","first-page":"e0226917","DOI":"10.1371\/journal.pone.0226917","volume":"15","author":"M Brown","year":"2020","unstructured":"Brown, M. et al. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. PLoS ONE 15, e0226917 (2020).","journal-title":"PLoS ONE"},{"key":"4043_CR27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/imt.11.10","volume":"3","author":"LF Dodson","year":"2011","unstructured":"Dodson, L. F., Hawkins, W. G. & Goedegebuure, P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 3, 517\u2013537 (2011).","journal-title":"Immunotherapy"},{"key":"4043_CR28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12957-015-0605-7","volume":"13","author":"H Dong","year":"2015","unstructured":"Dong, H. et al. Survivin expression and serum levels in pancreatic cancer. World J. Surg. Oncol. 13, 189 (2015).","journal-title":"World J. Surg. Oncol."},{"key":"4043_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ags3.12325","volume":"4","author":"I Hoshino","year":"2020","unstructured":"Hoshino, I. et al. Prognostic impact of p53 and\/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers. Ann. Gastroenterol. Surg. 4, 275\u2013282 (2020).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"4043_CR30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.surg.2004.05.023","volume":"136","author":"K Kami","year":"2004","unstructured":"Kami, K. et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136, 443\u2013448 (2004).","journal-title":"Surgery"},{"key":"4043_CR31","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/267539","volume":"2011","author":"S Koido","year":"2011","unstructured":"Koido, S. et al. Current immunotherapeutic approaches in pancreatic cancer. Clin. Dev. Immunol. 2011, 267539 (2011).","journal-title":"Clin. Dev. Immunol."},{"key":"4043_CR32","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00432-022-04013-1","volume":"148","author":"S Krieg","year":"2022","unstructured":"Krieg, S. et al. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis. J. Cancer Res Clin. Oncol. 148, 2235\u20132246 (2022).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"4043_CR33","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/cas.14099","volume":"110","author":"T Kubo","year":"2019","unstructured":"Kubo, T. et al. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: analysis of an autopsy series. Cancer Sci. 110, 2386\u20132395 (2019).","journal-title":"Cancer Sci."},{"key":"4043_CR34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ijc.20006","volume":"109","author":"B Kubuschok","year":"2004","unstructured":"Kubuschok, B. et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int. J. Cancer 109, 568\u2013575 (2004).","journal-title":"Int. J. Cancer"},{"key":"4043_CR35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.canlet.2007.01.003","volume":"252","author":"FH Schmitz-Winnenthal","year":"2007","unstructured":"Schmitz-Winnenthal, F. H. et al. Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett. 252, 290\u2013298 (2007).","journal-title":"Cancer Lett."},{"key":"4043_CR36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-9966-30-2","volume":"30","author":"JX Zhou","year":"2011","unstructured":"Zhou, J. X., Li, Y., Chen, S. X. & Deng, A. M. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J. Exp. Clin. Cancer Res. 30, 2 (2011).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"4043_CR37","doi-asserted-by":"crossref","first-page":"e004346","DOI":"10.1136\/jitc-2021-004346","volume":"10","author":"Z Abdulrahman","year":"2022","unstructured":"Abdulrahman, Z. et al. Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. J. Immunother. Cancer 10, e004346 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"4043_CR38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.175.2.647","volume":"175","author":"D DeRyckere","year":"2005","unstructured":"DeRyckere, D. & DeGregori, J. E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo. J. Immunol. 175, 647\u2013655 (2005).","journal-title":"J. Immunol."},{"key":"4043_CR39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcpt.13841","volume":"133","author":"CC Hsiao","year":"2023","unstructured":"Hsiao, C. C., Vos, E., van Gisbergen, K. & Hamann, J. The adhesion G protein-coupled receptor GPR56\/ADGRG1 in cytotoxic lymphocytes. Basic Clin. Pharmacol. Toxicol. 133, 286\u2013294 (2023).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"4043_CR40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/ijms23010311","volume":"23","author":"N Mustafa","year":"2021","unstructured":"Mustafa, N. et al. E2f2 attenuates apoptosis of activated T lymphocytes and protects from immune-mediated injury through repression of Fas and FasL. Int. J. Mol. Sci. 23, 311 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"4043_CR41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1189\/jlb.0211092","volume":"90","author":"YM Peng","year":"2011","unstructured":"Peng, Y. M. et al. Specific expression of GPR56 by human cytotoxic lymphocytes. J. Leukoc. Biol. 90, 735\u2013740 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"4043_CR42","volume":"15","author":"FC Sanna","year":"2024","unstructured":"Sanna, F. C. et al. IL-2 and TCR stimulation induce expression and secretion of IL-32beta by human T cells. Front. Immunol. 15, 1437224 (2024).","journal-title":"Front. Immunol."},{"key":"4043_CR43","volume":"8","author":"Y Tian","year":"2017","unstructured":"Tian, Y. et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat. Commun. 8, 1473 (2017).","journal-title":"Nat. Commun."},{"key":"4043_CR44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10018-1","volume":"10","author":"KL Truong","year":"2019","unstructured":"Truong, K. L. et al. Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4+ memory T cells. Nat. Commun. 10, 2263 (2019).","journal-title":"Nat. Commun."},{"key":"4043_CR45","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1128\/MCB.21.24.8547-8564.2001","volume":"21","author":"JW Zhu","year":"2001","unstructured":"Zhu, J. W. et al. E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol. Cell. Biol. 21, 8547\u20138564 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"4043_CR46","volume":"210","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors. Pharmacol. Res. 210, 107506 (2024).","journal-title":"Pharmacol. Res."},{"key":"4043_CR47","doi-asserted-by":"crossref","first-page":"E5980","DOI":"10.1073\/pnas.1720564115","volume":"115","author":"MP Correia","year":"2018","unstructured":"Correia, M. P. et al. Distinct human circulating NKp30+FcepsilonRIgamma+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proc. Natl Acad. Sci. USA 115, E5980\u2013E5989 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4043_CR48","doi-asserted-by":"crossref","unstructured":"Liu, J. G. et al. Characterizing the immune landscape of tumor-infiltrating lymphocytes in non-small cell lung cancer. Genes Immun. 26, 229\u2013241 (2025).","DOI":"10.1038\/s41435-025-00330-w"},{"key":"4043_CR49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105240","volume":"106","author":"J Mietz","year":"2024","unstructured":"Mietz, J. et al. Human effector CD8+ T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model. EBioMedicine 106, 105240 (2024).","journal-title":"EBioMedicine"},{"key":"4043_CR50","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.celrep.2017.10.082","volume":"21","author":"K Ikeda","year":"2017","unstructured":"Ikeda, K. et al. Slc3a2 mediates branched-chain amino-acid-dependent maintenance of regulatory T cells. Cell Rep. 21, 1824\u20131838 (2017).","journal-title":"Cell Rep."},{"key":"4043_CR51","volume":"19","author":"L Lin","year":"2024","unstructured":"Lin, L., Deng, L. & Bao, Y. Identifying crucial lncRNAs and mRNAs in hypoxia-induced A549 lung cancer cells and investigating their underlying mechanisms via high-throughput sequencing. PLoS ONE 19, e0307954 (2024).","journal-title":"PLoS ONE"},{"key":"4043_CR52","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abh1873","volume":"7","author":"N Weisshaar","year":"2022","unstructured":"Weisshaar, N. et al. Rgs16 promotes antitumor CD8+ T cell exhaustion. Sci. Immunol. 7, eabh1873 (2022).","journal-title":"Sci. Immunol."},{"key":"4043_CR53","volume":"43","author":"X Xu","year":"2023","unstructured":"Xu, X. et al. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients. Neoplasia 43, 100919 (2023).","journal-title":"Neoplasia"},{"key":"4043_CR54","volume":"35","author":"L Ye","year":"2021","unstructured":"Ye, L. & Jin, W. Identification of lncRNA-associated competing endogenous RNA networks for occurrence and prognosis of gastric carcinoma. J. Clin. Lab. Anal. 35, e24028 (2021).","journal-title":"J. Clin. Lab. Anal."},{"key":"4043_CR55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12872-024-04462-1","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Bioinformatics analysis of ferroptosis-related hub genes and immunoinfiltration in myocardial ischemia\/reperfusion following heart transplantation. BMC Cardiovasc. Disord. 25, 16 (2025).","journal-title":"BMC Cardiovasc. Disord."},{"key":"4043_CR56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.alit.2024.04.004","volume":"73","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. A micropeptide TREMP encoded by lincR-PPP2R5C promotes Th2 cell differentiation by interacting with PYCR1 in allergic airway inflammation. Allergol. Int. 73, 587\u2013602 (2024).","journal-title":"Allergol. Int."},{"key":"4043_CR57","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.19.00177","volume":"37","author":"AB Hont","year":"2019","unstructured":"Hont, A. B. et al. Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study. J. Clin. Oncol. 37, 2349\u20132359 (2019).","journal-title":"J. Clin. Oncol."},{"key":"4043_CR58","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"4043_CR59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512\u2013516 (2017).","journal-title":"Nature"},{"key":"4043_CR60","doi-asserted-by":"crossref","DOI":"10.1177\/11795549251331759","volume":"19","author":"S El Zaitouni","year":"2025","unstructured":"El Zaitouni, S. et al. Potency and safety of KRAS G12Cinhibitors in solid tumors: a systematic review. Clin. Med. Insights Oncol. 19, 11795549251331759 (2025).","journal-title":"Clin. Med. Insights Oncol."},{"key":"4043_CR61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"4043_CR62","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"4043_CR63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/cancers17040704","volume":"17","author":"N Sobhani","year":"2025","unstructured":"Sobhani, N., Pittacolo, M., D\u2019Angelo, A. & Marchegiani, G. Recent anti-KRAS(G12D) therapies: a \u2018possible impossibility\u2019 for pancreatic ductal adenocarcinoma. Cancers 17, 704 (2025).","journal-title":"Cancers"},{"key":"4043_CR64","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"4043_CR65","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/cancers16101808","volume":"16","author":"OT Olaoba","year":"2024","unstructured":"Olaoba, O. T. et al. Driver mutations in pancreatic cancer and opportunities for targeted therapy. Cancers 16, 1808 (2024).","journal-title":"Cancers"},{"key":"4043_CR66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12029-025-01237-5","volume":"56","author":"K Zhao","year":"2025","unstructured":"Zhao, K. et al. Neoadjuvant pembrolizumab enables successful downstaging and resection of borderline resectable MSI-H\/dMMR pancreatic ductal adenocarcinoma: a case report and literature review. J. Gastrointest. Cancer 56, 112 (2025).","journal-title":"J. Gastrointest. Cancer"},{"key":"4043_CR67","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1136\/jitc-2021-003255","volume":"10","author":"R Garcia-Carbonero","year":"2022","unstructured":"Garcia-Carbonero, R. et al. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J. Immunother. Cancer 10, e003255 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"4043_CR68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","volume":"25","author":"BL Musher","year":"2024","unstructured":"Musher, B. L. et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study. Lancet Oncol. 25, 488\u2013500 (2024).","journal-title":"Lancet Oncol."},{"key":"4043_CR69","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"4043_CR70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12029-025-01165-4","volume":"56","author":"MT McMillan","year":"2025","unstructured":"McMillan, M. T. & Soares, K. C. Advances in vaccine-based therapies for pancreatic cancer. J. Gastrointest. Cancer 56, 62 (2025).","journal-title":"J. Gastrointest. Cancer"},{"key":"4043_CR71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249\u2013258 (2017).","journal-title":"Mol. Ther."},{"key":"4043_CR72","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","volume":"8","author":"S Sukumaran","year":"2018","unstructured":"Sukumaran, S. et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 8, 972\u2013987 (2018).","journal-title":"Cancer Discov."},{"key":"4043_CR73","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1158\/2326-6066.CIR-22-0115","volume":"10","author":"P Bajgain","year":"2022","unstructured":"Bajgain, P. et al. Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas ligandexpressing solid tumors. Cancer Immunol. Res. 10, 1370\u20131385 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"4043_CR74","doi-asserted-by":"crossref","first-page":"1299512","DOI":"10.3389\/fimmu.2023.1299512","volume":"14","author":"K Koukoulias","year":"2023","unstructured":"Koukoulias, K. et al. Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay. Front. Immunol. 14, 1299512 (2023).","journal-title":"Front. Immunol."},{"key":"4043_CR75","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/bioinformatics\/btx763","volume":"34","author":"Y Yu","year":"2018","unstructured":"Yu, Y., Ouyang, Y. & Yao, W. shinyCircos: an R\/Shiny application for interactive creation of Circos plot. Bioinformatics 34, 1229\u20131231 (2018).","journal-title":"Bioinformatics"},{"key":"4043_CR76","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1109\/TVCG.2011.185","volume":"17","author":"M Bostock","year":"2011","unstructured":"Bostock, M., Ogievetsky, V. & Heer, J. D(3): data-driven documents. IEEE Trans. Vis. Comput. Graph 17, 2301\u20132309 (2011).","journal-title":"IEEE Trans. Vis. Comput. Graph"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04043-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:03:07Z","timestamp":1769007787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04043-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04043-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L.M. receives research funding from Diakonos and LOKON and has a consulting agreement with Gnubiotics. B.J.G. owns QBRegulatory Consulting, which has consulting agreements with Tessa Therapeutics, Marker Therapeutics, LOKON and AlloVir. H.E.H. is a co-founder with equity in AlloVir and Marker Therapeutics, has served on advisory boards for Tessa Therapeutics, Kiadis, Novartis, Gilead Biosciences, Fresh Wind Biotechnologies and GSK, has share options in March Biosciences and CoRegen and received research support from Kuur Therapeutics and Tessa Therapeutics. C.M.R. and M.K.B. have stock and other ownership interests with Coya, Bluebird Bio, Tessa Therapeutics, Marker Therapeutics, AlloVir, Walking Fish, Allogene Therapeutics, Memgen, Kuur Therapeutics, Bellicum Pharmaceuticals, TScan Therapeutics, Abintus Bio and March Biosciences, consulting or advisory roles with Abintus Bio, Adaptimmune, Brooklyn Immunotherapeutic, Onk Therapeutics, Tessa Therapeutics, Memgen, Torque, Walking Fish Therapeutics, TScan Therapeutics, Marker Therapeutics and Turnstone Bio and receive research funding from Kuur Therapeutics. A.M.L. is a co-founder and equity holder for AlloVir and Marker Therapeutics and was a consultant to AlloVir. S.V. and M.K. were consultants to AlloVir. B.G.S. receives research funding from Merck and AstraZeneca and has a consulting agreement with Boehringer Ingelheim. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}